Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
Miglino M, Berisso G, Grasso R, Canepa L, Clavio M, Pierri I, Pietrasanta D, Gatto S, Varaldo R, Ballerini F, Verdiani S, Casarino L, DeStefano F, Sessarego M, Dominietto A, Raiola AM, Bregante S, di Grazia C, Gobbi M, Bacigalupo A. Miglino M, et al. Among authors: sessarego m. Bone Marrow Transplant. 2002 Nov;30(9):579-85. doi: 10.1038/sj.bmt.1703659. Bone Marrow Transplant. 2002. PMID: 12407432
Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, Lamparelli T, Occhini D, Mordini N, Bregante S, Figari O, Benvenuto F, Sessarego M, Fugazza G, Carlier P, Valbonesi M. Bacigalupo A, et al. Among authors: sessarego m. Bone Marrow Transplant. 1997 May;19(9):927-32. doi: 10.1038/sj.bmt.1700762. Bone Marrow Transplant. 1997. PMID: 9156268 Clinical Trial.
Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
Lamparelli T, van Lint MT, Gualandi F, Raiola AM, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Bregante S, Berisso G, Dominietto A, Di Grazia C, Bruno B, Sessarego M, Casarino L, Verdiani S, Bacigalupo A. Lamparelli T, et al. Among authors: sessarego m. Bone Marrow Transplant. 2000 Dec;26(12):1305-11. doi: 10.1038/sj.bmt.1702719. Bone Marrow Transplant. 2000. PMID: 11223970
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Mordini N, Berisso G, Bregante S, Frassoni F, Sessarego M, Fugazza G, Di Stefano F, Pitto A, Bacigalupo A. Raiola AM, et al. Among authors: sessarego m. Br J Haematol. 2000 Jun;109(4):716-21. doi: 10.1046/j.1365-2141.2000.02123.x. Br J Haematol. 2000. PMID: 10929020 Free article.
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M. Clavio M, et al. Among authors: sessarego m. Leuk Lymphoma. 2001 Jan;40(3-4):305-13. doi: 10.3109/10428190109057929. Leuk Lymphoma. 2001. PMID: 11426552 Clinical Trial.
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M. Clavio M, et al. Among authors: sessarego m. J Exp Clin Cancer Res. 2002 Dec;21(4):481-7. J Exp Clin Cancer Res. 2002. PMID: 12636093
145 results